 |
市场调查报告书
商品编码
1983321
疼痛管理药物市场：按药物类别、通路和地区划分Pain Management Drugs Market, By Drug Class, By Distribution Channel, By Geography |
||||||
2026年，疼痛管理药物市场规模估计为884亿美元，预计2033年将达到1,131.5亿美元。预计从2026年到2033年，该市场将以3.6%的复合年增长率成长。
| 分析范围 | 分析详情 | ||
|---|---|---|---|
| 基准年 | 2025 | 市场规模（2026 年） | 884亿美元 |
| 效能数据 | 2020-2024 | 预测期 | 2026-2033 |
| 预测期（2026-2033 年）复合年增长率 | 3.60% | 预计金额（2033 年） | 1131.5亿美元 |
镇痛药是一类透过作用于疼痛受体来缓解疼痛症状的药物。这些药物包括鸦片类药物、非类固醇消炎剂（NSAIDs）、抗惊厥药、抗忧郁症和肌肉鬆弛剂。这些药物用于治疗疼痛，其适应症列于附加檔中，部分药物也用于仿单标示外。例如，抗惊厥药和抗忧郁症最初分别用于治疗癫痫和忧郁症。然而，这些药物已被证实对缓解疼痛症状有效，因此也被仿单标示外用于镇痛。此外，阿片类药物主要用于治疗急性和慢性疼痛。这导致患者自行用药，造成阿片类药物製剂的滥用和过量。另外，许多药物的专利保护期已过多年，其学名药已广泛上市。非处方止痛药包括Fentanyl、氢吗啡酮、羟考酮、阿斯匹灵和Diazepam。
市场动态
全球疼痛管理药物市场受多种因素驱动，例如缺乏替代疗法以及学名药生产商的强大影响力。例如，根据美国国家生物技术资讯中心 (NCBI) 2018 年 2 月发布的数据，许多主要药物，如奥施康定 (OxyContin)、奥帕纳缓释片 (Opana ER) 和Celebrex)的非专利保护期已过，非专利药生产商开发出的产品种类，推动了疼痛管理药物市场的增长繁多。在预测期内，持续的药物需求和便捷的取得途径预计将继续推动镇痛药的使用。这些药物在改善治疗效果方面的显着疗效以及癌症（可导致癌症疼痛）等疾病盛行率的不断上升，正在促进疼痛管理药物市场的成长。然而，这些药物可能存在危及生命的副作用（包装上的黑框警告已对此进行了说明），以及主要企业研发投入的不足，预计将阻碍疼痛管理药物市场的成长。
本报告的主要特点
- 本报告指出了各个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
- 此外，它还提供了有关市场驱动因素和限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
- 本节根据以下参数，介绍全球疼痛管理药物市场中主要企业的概况：公司概况、产品系列、主要亮点、财务表现和策略。
- 本报告中的见解将使负责人和企业经营团队能够就未来的产品发布、产品线更新、市场扩张和行销策略做出明智的决策。
- 《全球疼痛管理药物市场》报告面向该行业的各种相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
- 相关人员可以透过分析全球疼痛管理药物市场中使用的各种策略矩阵来促进决策。
目录
第一章：分析目标与假设
- 分析目的
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
第三章：市场动态、监管与趋势分析
- 市场动态
- 影响分析
- 主要亮点
- 法规环境
- 产品上市及核准
- PEST分析
- 波特五力分析
- 市场机会
- 法规环境
- 主要进展
- 产业趋势
第四章：全球疼痛管理药物市场：依药物类别划分（2020-2033 年）
- 阿片类药物
- NSAIDs
- 抗惊厥药物
- 抗忧郁症
- 其他的
第五章：全球疼痛管理药物市场：依通路划分（2020-2033 年）
- 医院药房
- 零售药房
- 网路药房
第六章：全球疼痛管理药物市场：按地区划分（2020-2033 年）
- 北美洲
- 我们
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 亚太其他地区
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东国家
- 非洲
- 南非
- 北非
- 中非
第七章 竞争情势
- Pfizer, Inc.
- Sanofi SA
- Mylan NV
- Teva Pharmaceutical Industries Ltd.
- Eily, Lilly, and Company
- Abbott Laboratories
- Purdue Pharma LP
- GlaxoSmithKline Plc
- Johnson &Johnson
- F. Hoffmann La Roche Ltd.
第八章 分析师建议
- 机会
- 分析师意见
- Coherent Opportunity Map (COM)
第九章 参考文献与分析方法
- 参考
- 分析方法
- 关于 Coherent Market Insights
Pain Management Drugs Market is estimated to be valued at USD 88.4 Bn in 2026 and is expected to reach USD 113.15 Bn by 2033, growing at a compound annual growth rate (CAGR) of 3.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 88.4 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.60% | 2033 Value Projection: | USD 113.15 Bn |
Pain management medications are specific drug classes, which have pharmacological actions on pain receptors and work against the pain symptoms. These medications include opioids, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants, muscle relaxants, and others. These medications can be used for pain management of conditions, as indicated on label and some medications have off-label uses. For instance, anticonvulsants and antidepressants were originally used for the management of epilepsy and depression respectively. However, these medications have shown activity against pain indications and are prescribed for pain management as off-label indication. Moreover, opioids are majorly prescribed for the management of acute as well as chronic pain. This has also resulted in self-medication by patients, resulting in misuse or overdose of opioid containing drug products. Moreover, majority of the drugs have lost patent protection over the years and generic versions of the same are widely available in the market. Commercially available pain management drugs include Fentanyl, Hydromorphone, Oxycodone, Aspirin, Diazepam, and others.
Market Dynamics
The global pain management drugs market is driven by factors such as absence of alternative therapies and high presence of generic drug manufacturers in the market. For instance, in February 2018, according to data published by National Center for Biotechnology Information, increasing number of major drugs such as OxyContin, Opana ER, and Celebrex have lost patent protection due to which generic manufacturers have developed generic version with product variations fostering growth of the pain management drugs market. Continuous requirement of the medication coupled with easy availability is expected to boost the adoption of pain drugs over the forecast period. Proven effectiveness of these medications in improving medical outcomes and increasing prevalence of disorders such as cancer (leading to cancer pain) are fueling growth of the pain management drugs market. However, life threatening side effects associated with these medications, as indicated by the black box warning on the packaging, as well as lack of research and development by major players are expected to hinder growth of the pain management drugs market.
Key features of the study
- This report provides an in-depth analysis of the global pain management drugs market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global pain management drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Abbott Laboratories, Purdue Pharma L.P., GlaxoSmithKline Plc, Johnson & Johnson, and F. Hoffmann La Roche Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global pain management drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pain management drugs market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2026 - 2033)
- Opioids
- NSAIDs
- Anticonvulsants
- Antidepressants
- Others
- Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
- Key Players Insights
- Pfizer, Inc.
- Sanofi S.A.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Eily, Lilly, and Company
- Abbott Laboratories
- Purdue Pharma L.P.
- GlaxoSmithKline Plc
- Johnson & Johnson
- F. Hoffmann La Roche Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Pain Management Drugs Market, By Drug Class
- Global Pain Management Drugs Market, By Distribution Channel
- Global Pain Management Drugs Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend
4. Global Pain Management Drugs Market, By Drug Class, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Opioids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- NSAIDs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Anticonvulsants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
5. Global Pain Management Drugs Market, By Distribution Channel, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
6. Global Pain Management Drugs Market, By Region, 2020 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
7. Competitive Landscape
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eily, Lilly, and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Purdue Pharma L.P.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline Plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- F. Hoffmann La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
8. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
9. References and Research Methodology
- References
- Research Methodology
- About us
